Waal-Manning, H. J. published the artcileOne year follow-up of hyperuricemic hypertensive patients treated with tienilic acid or a diuretic with or without uric acid-lowering drugs, Product Details of C13H8Cl2O4S, the main research area is tienilate blood pressure; serum urate tienilate; liver function tienilate.
Fifty-four hypertensive, hyperuricemic patients were pair-matched for age, sex, and current therapy (diuretic, uric acid (I) [69-93-2]-lowering drug) and one member of each pair was assigned to treatment with tienilic acid (II) [40180-04-9] (188 mg/day) while the other member continued on the previous therapy; blood pressure control was equally good in the II-treated and control groups but serum I levels were lower in II-treated patients. Liver function tests changed from pretrial results in 9 patients; minor increases in alk. phosphatase occurred in 8 of these patients (4 in the II treatment group and 4 in the control group). However the 9th patient (receiving II) showed a marked increase in serum aspartate transaminase and eventually rises in alk. phosphatase and bilirubin; these values reverted to normal after stopping II.
Clinical Science published new progress about Blood pressure. 40180-04-9 belongs to class benzothiophene, name is 2-(2,3-Dichloro-4-(thiophene-2-carbonyl)phenoxy)acetic acid, and the molecular formula is C13H8Cl2O4S, Product Details of C13H8Cl2O4S.
Referemce:
Benzothiophene – Wikipedia,
Benzothiophene | C8H6S – PubChem